Search peptides, terms, sources/
Research source · 2024

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
98 participants with elevated baseline liver fat, drawn from the Phase 2 obesity trial population
Sample size
98
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Small sub-study sample; drawn from the same overall programme as Source 1, not a fully independent trial.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.